OUR FOCUS ON:
Transforming the lives of patients with metabolic disorders

Sanofi contributes a wealth of medical data to the American Diabetes Association scientific program

- More than 70 Sanofi-related contributions at ADA 2018
- 30 abstracts relating to Toujeo® (insulin glargine 300 Units/mL)

### Abstract 301-OR: BRIGHT

**Similar Glycemic Control and Less or Comparable Hypoglycemia with Insulin Glargine 300 U/mL (Gla-300) vs Degludec 100 U/mL (Ideg-100) in Insulin-Naïve Adults with T2DM on Antihyperglycemic Drugs ± GLP-1 RAs: The BRIGHT Randomized Study**

Monday, June 25, 1500 EDT

### Abstract 212-OR: inTandem1

**52-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1, NCT02384941)**

Buse J, et al. Oral presentation
Sunday, June 24, 1545 EDT

### Abstract 6-LB: ODYSSEY OUTCOMES

(in partnership with Regeneron)

**Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes — Prespecified Analyses of ODYSSEY OUTCOMES**

Ray K, et al. Moderated poster discussion
Sunday, June 24, 1200 EDT

### SANOFI: ADA OFFICIAL SYMPOSIUM

**Real World Evidence in Diabetes**
Oral presentations
Friday, June 22, 1400 – 1600 EDT

**SGLT Inhibition for Type 1 Diabetes Mellitus Management – How Far Have We Gone?**
Oral presentations
Tuesday, June 26, 1015 – 1215 EDT

*The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) have conditionally accepted ZYNQUISTA as the trade name for sotagliflozin.

**About Sanofi**
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life.

For medical journalists outside the U.S. only
Follow us on @SanofiDCV